Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 4;12:985470. doi: 10.3389/fonc.2022.985470

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Yi, Han and Li

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

MiR-625 targets ZEB2 in endometrial cancer cells. (A) Venn analysis of predicted miR-625 target genes. (B) The luciferase reporter plasmids contained wild-type (WT) and mutated (MUT) miR-625 binding sites in the ZEB2 3´-UTR sequence. (C) ZEB2 mRNA expression in endometrial cancer cells and normal cells. (D) Luciferase reporter assay of endometrial cancer cells transfected with miR-625 mimic, miR-625 inhibitor, and luciferase reporter plasmids containing WT or MUT ZEB2 3´-UTR. (E) Western blot analysis of ZEB2 and actin expression in endometrial cancer cells transfected as indicated. (F) The correlation between miR-625 and ZEB2 expression in TCGA endometrial cancer samples. ***P < 0.001.